A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens

Journal of Immunology

Volumn 164, Issue 11, 2000, Pages 5583-5589

  El Mir, Samir ^a   Triebel, Frédéric ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGIC AGENT; LYMPHOCYTE ACTIVATION GENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; DRUG EFFECT; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0034114926     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.11.5583     Document Type: Article

References (23)

1. Triebel, F., S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevée, E. Viegas-Pequignot, and T. Hercend. 1990. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 171:1393.
2. Baixeras, E., B. Huard, C. Miossec, S. Jitsukawa, M. Martin, T. Hercend, C. Auffray, F. Triebel, and D. Piatier-Tonneau. 1992. Characterization of the lymphocyte activation gene 3-encoded protein: a new ligand for human leukocyte antigen class II antigens. J. Exp. Med. 176:327.
3. Hannier, S., M. Tournier, G. Bismuth, and F. Triebel. 1998. CD3/TCR complex-associated LAG-3 molecules inhibit CD3/TCR signaling. J. Immunol. 161:4058.
4. Hannier, S., and F. Triebel. 1999. The MHC class II ligand LAG-3 is co-distributed with CD8 and CD3/TCR molecules after their engagement by mAbs or peptide/MHC class I complexes. Int. Immunol. 11:1745.
5. Sakihama, T., A. Smolyar, and E. L. Reinherz. 1995. Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc. Natl. Acad. Sci. USA 92:6444.
6. Huard, B., R. Mastrangeli, P. Prigent, D. Bruniquel, S. Donini, N. El-Tayar, B. Maigret, M. Dreano, and F. Triebel. 1997. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl. Acad. Sci. USA 94:5744.
7. Huard, B., P. Prigent, M. Tournier, D. Bruniquel, and F. Triebel. 1995. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur. J. Immunol. 25: 2718.
8. Avice, M. N., M. Sarfati, F. Triebel, G. Delespesse, and C. E. Demeure. 1999. Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-α and IL-12 production by monocytes and dendritic cells. J. Immunol. 162:2748.
9. Prigent, P., S. E. Mir, M. Dreano, and F. Triebel. 1999. LAG-3 induces tumor regression and antitumor immune responses in vivo. Eur. J. Immunol. 29: 3867.
10. + T cell clone response following LAG-3 binding. Eur. J. Immunol. 26:1180.
11. Schirmbeck, R., K. Melber, T. Mertens, and J. Reimann. 1994. Selective stimulation of murine cytotoxic T cell and antibody responses by particulate or monomeric hepatitis B virus surface (S) antigen. Eur. J. Immunol. 24:1088.
12. + cytotoxic T lymphocyte responses in vivo. J. Immunol. 152:1110.
13. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283.
14. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.
15. Ke, Y., Y. Li, and J. A. Kapp. 1995. Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur. J. Immunol. 25:549.
16. + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 344:873.
17. Collins, D. S., K. Findlay, and C. V. Harding. 1992. Processing of exogenous liposome-encapsulaled antigens in vivo generates class I MHC-restricted T cell responses. J. Inmunol. 148:3336.
18. Lopes, L. M., and B. M. Chain. 1992. Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen. Eur. J. Immunol. 22:287.
19. Wu, J. Y., B. H. Gardner, C. I. Murphy, J. R. Seals, C. R. Kensil, J. Recchia, G. A. Beltz, G. W. Newman, and M. J. Newman. 1992. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine. J. Immunol. 148:1519.
20. + cytotoxic T lymphocyte responses. J. Immunol. 148:2357.
21. Kensil, C. R., J. Y. Wu, C. A. Anderson, D. A. Wheeler, and J. Amsden. 1998. QS-21 and QS-7: purified saponin adjuvants. In Modulation of the Immune Response to Vaccine Antigens, Vol. 92. F. Brown, and L. R. Haaheim, eds. Karger, Basel, Switzerland, p.41.
22. Krieg, A. M., L. Love-Homan, A. K. Yi, and J. T. Harty. 1998. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol. 161:2428.
23. Chen, W., U. Syldath, K. Bellmann, V. Burkart, and H. Kolb. 1999. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J. Immunol. 162:3212.